Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-traumatic Neuralgia, Followed by a Double Blind Safety Extension and an Open-label Safety Extension.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2018
Price :
$35
*
At a glance
- Drugs Fulranumab (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 31 Aug 2012 Results presented at the 14th World Congress on Pain.
- 27 Aug 2012 Primary endpoint 'Pain-intensity' (assessed on a numerical rating scale) has not been met (based on information presented at 14th World Congress on Pain); however, only 111 of the planned 200 patients were enrolled.
- 30 Mar 2012 Actual patient number is 112 according to ClinicalTrials.gov.